• Encompass Health has outlined its expansion in the Philadelphia suburbs, with a more than US$100 million investment in two 50-bed inpatient rehabilitation hospitals in Glen Mills and Lower Providence, the first of which opened as Encompass Health Concordville in May 2026 under CEO Lauren Grieder.
• This build-out, which makes Concordville the company’s 10th hospital in Pennsylvania, highlights Encompass Health’s push to deepen its regional footprint in complex inpatient rehabilitation care.
• We’ll now examine how this more than US$100 million Pennsylvania expansion could influence Encompass Health’s investment narrative and growth outlook.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

Encompass Health Investment Narrative Recap

To own Encompass Health, you need to be comfortable with a capital intensive, hospital build out model that leans on sustained demand for complex inpatient rehab. The more than US$100 million Pennsylvania expansion fits this de novo playbook, but does not materially change the near term focus on Q4 2025 results and on whether staffing and wage pressures can be managed without eroding margins.

Among recent announcements, the upcoming Q4 2025 earnings release and call on 5–6 February 2026 looks most relevant, as it should give investors updated insight into how expansion projects like Concordville are being funded, their preopening cost impact, and how management is thinking about balancing growth with free cash flow and leverage.

Yet while new hospitals can support growth, investors should still be aware of the risk that persistent labor shortages could...

Encompass Health's narrative projects $7.2 billion revenue and $711.6 million earnings by 2028. This requires 8.1% yearly revenue growth and about a $189 million earnings increase from $522.4 million today.

Uncover how Encompass Health's forecasts yield a $140.33 fair value, a 40% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community value Encompass Health between US$140 and US$366 per share, highlighting very different expectations. Against that wide range, the company’s heavy de novo build program and associated capex requirements raise important questions about future returns on invested capital and financial flexibility.

Explore 3 other fair value estimates on Encompass Health - why the stock might be worth just $140.33!

Build Your Own Encompass Health Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Encompass Health research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Encompass Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Encompass Health's overall financial health at a glance.

Looking For Alternative Opportunities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 38 companies in the world exploring or producing it. Find the list for free.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.